8-K: Maze Therapeutics Secures $150M, MZE782 Phase 1 Positive

Maze Therapeutics raises $150M; MZE782 Phase 1 positive.

Summary

• Maze Therapeutics entered into a securities purchase agreement for an oversubscribed private placement, raising approximately $150.0 million in gross proceeds before deducting fees and expenses.
• The private placement involved the sale of 4,000,002 shares of common stock at a purchase price of $16.25 per share and 5,231,090 pre-funded warrants at $16.249 per warrant, with an exercise price of $0.001 per warrant share.
• Proceeds from the private placement, combined with existing cash, will be used to advance MZE829 in APOL1-mediated kidney disease, initiate Phase 2 clinical trials for MZE782 in phenylketonuria (PKU) and chronic kidney disease (CKD), progress research and discovery programs, further develop the Compass platform, and for general corporate purposes.
• Positive first-in-human Phase 1 trial results for MZE782 demonstrated robust target engagement and compelling pharmacodynamic effects, exceeding expectations.
• MZE782 showed dose-dependent increases in 24-hour urinary phenylalanine (Phe) excretion (up to 42-fold) and glutamine (Gln) excretion (up to 68-fold) in healthy volunteers.
• An initial dose-dependent eGFR dip was observed, similar to SGLT2 inhibitors, suggesting a potential kidney protective effect in CKD patients.
• MZE782 was well tolerated across all doses with an excellent safety profile, reporting no serious adverse events or treatment-related adverse events leading to discontinuation.

Sentiment

Score: 9

Explanation: The filing reports a successful, oversubscribed capital raise and highly positive Phase 1 clinical trial results that exceeded expectations, demonstrating strong safety and efficacy signals for a key pipeline asset. This significantly de-risks the asset and provides substantial funding for future development, indicating a very strong positive outlook for the company.

Positives

• Oversubscribed private placement raising $150.0 million, indicating strong investor confidence and providing substantial capital.
• Positive Phase 1 trial results for MZE782, establishing proof of mechanism and exceeding expectations for a potent, oral SLC6A19 inhibitor.
• MZE782 demonstrated robust target engagement with dose-dependent increases in urinary phenylalanine (up to 42-fold) and glutamine (up to 68-fold) excretion, which are validated biomarkers.
• Observed dose-dependent initial eGFR dip, similar to SGLT2 inhibitors, supporting a potential kidney protective effect in CKD.
• MZE782 exhibited an excellent safety profile, with no serious adverse events or treatment-related discontinuations across all doses.
• The results clinically validate the company's Compass platform, with MZE782 being the third clinical program to emerge from it.
• The private placement attracted participation from both new and existing institutional investors, including prominent healthcare-dedicated funds.

Risks

• Actual results, levels of activity, safety, performance, or events and circumstances could differ materially from forward-looking statements.
• Risks and uncertainties related to the company's ability to advance MZE829, MZE782, and its other therapeutic candidates.
• Challenges in obtaining regulatory approval and ultimately commercializing therapeutic candidates.
• Uncertainty regarding the timing and results of preclinical studies and clinical trials.
• Risks related to the company's ability to fund development activities and achieve development goals.
• Challenges in protecting intellectual property.
• General business and economic conditions, including macroeconomic factors like inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises.

Future Outlook

Maze Therapeutics intends to use the proceeds from the private placement to advance the development of MZE829 in APOL1-mediated kidney disease, initiate Phase 2 clinical trials of MZE782 in both phenylketonuria and chronic kidney disease in 2026, continue progress on research and discovery programs, and further develop its Compass platform. The company expects MZE782's observed eGFR dip to correlate with a slower rate of eGFR decline and better preservation of kidney function in CKD patients over longer periods.

Management Comments

• "These first-in-human results for MZE782 mark an important milestone, demonstrating an excellent safety profile, robust target engagement and compelling pharmacodynamic effects, consistent with our therapeutic hypothesis." Harold Bernstein, M.D., Ph.D., president of R&D and chief medical officer of Maze.
• "The rapid and profound increase in urinary phenylalanine excretion confirms SLC6A19 inhibition in healthy individuals that we anticipate will translate to meaningful reductions in plasma phenylalanine levels in patients with PKU, based on the biology of this transporter." Harold Bernstein, M.D., Ph.D.
• "We also observed dose-dependent changes in eGFR in healthy individuals with MZE782, similar to those seen with SGLT2 inhibitors, suggesting a potential beneficial effect on kidney physiology in CKD patients." Harold Bernstein, M.D., Ph.D.
• "We look forward to advancing MZE782 into Phase 2 studies in both PKU and CKD in 2026." Harold Bernstein, M.D., Ph.D.
• "These findings also serve as important clinical validation of our Compass platform. MZE782 is the third clinical program to come out of our Compass platform, further demonstrating our ability to harness the power of human genetics to develop small molecule precision medicines designed to transform the lives of patients with kidney and metabolic diseases." Harold Bernstein, M.D., Ph.D.

Industry Context

The positive Phase 1 results for MZE782, particularly the observed eGFR dip similar to SGLT2 inhibitors, position Maze Therapeutics with a potential first-in-class therapy for CKD and a best-in-class therapy for PKU. SGLT2 inhibitors are a well-established class of drugs for kidney protection, and MZE782's complementary yet distinct mechanism of SLC6A19 inhibition could offer a new therapeutic avenue, potentially expanding the treatment landscape for kidney and metabolic diseases.

Comparison to Industry Standards

• MZE782's dose-dependent initial eGFR dip is similar in magnitude to what has been observed in patients initiating SGLT2 and RAAS inhibitors, which are established renoprotective therapies.
• Loss-of-function mutations in SLC6A19, as seen in Hartnup disease (a generally benign condition), support the potential safety of SLC6A19 inhibition, providing a strong rationale for MZE782's therapeutic approach.
• MZE782 offers a genotypeand PAH-agnostic, oral approach to lowering plasma Phe in PKU, potentially positioning it as a best-in-class therapy compared to existing treatments that may have limitations.

Stakeholder Impact

• Shareholders: Potential for increased share value due to successful capital raise and positive clinical data; dilution from new share issuance, but at a premium to last closing price.
• Patients: Hope for new precision medicines for APOL1-mediated kidney disease, phenylketonuria, and chronic kidney disease.
• Investors (new and existing): Opportunity to participate in a growing biopharmaceutical company with promising pipeline assets.
• Employees: Continued employment and potential for growth as pipeline advances.

Next Steps

• Closing of the private placement on or about September 12, 2025.
• Company to prepare and file a registration statement for resale of the securities within 60 days of the private placement closing.
• Advance the development of MZE829 in patients with APOL1-mediated kidney disease.
• Initiate Phase 2 clinical trials of MZE782 in both phenylketonuria (PKU) and chronic kidney disease (CKD) in 2026.
• Continue progress on research and discovery programs.
• Further the development of its Compass platform.
• Use proceeds for working capital and other general corporate purposes.

Key Dates

Recommendation

The combination of a highly successful, oversubscribed $150 million private placement at a premium to the last closing price, coupled with exceptionally positive Phase 1 clinical trial results for MZE782 that exceeded expectations and demonstrated a strong safety profile and clear proof of mechanism, significantly de-risks the company's pipeline and provides ample capital for advancing multiple programs. The clinical validation of the Compass platform further strengthens the long-term growth prospects. These factors collectively present a compelling investment opportunity.

Keywords

Maze Therapeutics, MAZE, Biopharmaceutical, Private Placement, MZE782, MZE829, Phase 1 Trial, Phase 2 Trial, Phenylketonuria, PKU, Chronic Kidney Disease, CKD, APOL1-mediated kidney disease, AMKD, SLC6A19 inhibitor, Compass platform, Clinical-stage, Drug Development, Biotech, Equity Raise, Warrants